ea0094p54 | Metabolism, Obesity and Diabetes | SFEBES2023
Ali Sadaf
, Paisey Richard
, da Silva Xavier Gabriela
, Hiwot Tarekegn
Background: Glucagon-like-peptide-1 (GLP-1) has been shown to improve body weight and glycaemic control in patients with common obesity and type 2 diabetes. Whether it confers the same metabolic benefits in monogenic syndromic obesity is unknown. This observational study aimed to examine the real-world efficacy of GLP-1 analogues in Alström syndrome (ALMS), a form of monogenic obesity.Method: We screened all 72 UK a...